The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Acute therapies continue to report strong growth compared to chronic ones.
The combined entity will have 12 hospitals with 3,666 beds
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
Subscribe To Our Newsletter & Stay Updated
